Ascletis PharmaASCLF -4.00%38 Gross Margin % is 43.28% as of Dec. 2025, which is 11% below its 10-year median of 48.44. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, Ascletis Pharma ranks worse than 80.05% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ascletis Pharma had a gross margin of 43.28% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ascletis Pharma Gross Margin % Related Terms
Ascletis Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Ascletis Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ascletis Pharma (ASCLF) has a Gross Margin % of 43.28% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Ascletis Pharma and its competitors. This is 11% below median its historical median of 48.44. According to the industry distribution chart, Ascletis Pharma ranks #586 out of 732 companies in the Biotechnology industry, placing it in the top 80.1%.
Is Ascletis Pharma's Gross Margin % too high?
Ascletis Pharma's current Gross Margin % of 43.28% is 11% below median its 10-year median of 48.44. The Biotechnology industry median Gross Margin % is 60.91. Ascletis Pharma's value of 43.28% is 28.9% below this industry median. Based on the distribution chart, Ascletis Pharma ranks #586 out of 732 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #586 out of 732 companies for Gross Margin %. This places Ascletis Pharma in the lower half of its industry. The industry median Gross Margin % is 60.91. Ascletis Pharma's value of 43.28% is 28.9% below this benchmark. While the company's 10-year median is 48.44 vs. the industry median of 60.91, Ascletis Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Gross Margin % of 43.28% is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Gross Margin % is 43.28%, which is 11% below median its own 10-year median of 48.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Gross Margin % is 43.28%, which is 11% below median its 10-year median of 48.44 and 28.9% below the Biotechnology industry median of 60.91. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Gross Margin % is 43.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Gross Margin %: 43.28% (11% below median its 10-year median of 48.44)
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
Industry Position: 28.9% below the Biotechnology median (#586 of 732)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
